INTRODUCTION: Academic detailing, typically conducted by impartial advisors, can optimize prescribing behavior. The objective of this prospective controlled trial was to determine if evidence-based detailing conducted by a pharmaceutical manufacturer can also improve physician prescribing habits.
MATERIALS AND METHODS: Physicians in eight Ontario regions were randomized to receive manufacturer detailing at least twice over six months using either an evidence-based educational pamphlet reviewing antibiotic therapy for acute otitis media or regular detailing. Relative percent changes of market share pre- and post-intervention were measured using a retail pharmacy administrative prescription database assembled by IMS Canada. Multivariable linear regression analysis was done using pre- and post-intervention market share differences for each product as the dependent variable and accounting for baseline market share, sex of prescribing physician, prescribing physician location, and years since graduation as covariates.
RESULTS: Change in market share for amoxicillin, pivampicillin, erthyromycin-sulfisoxazole, or any third-line agents (cefixime, amoxicillin clavulanate, or cefaclor) was not significantly different between intervention and control regions. Trimethoprim-sulfamethoxazole market share decreased significantly between intervention and control regions. Most variation in prescribing was accounted for by the differences in baseline antibiotic market shares, sex of the prescribing physician, and the years since physician graduation.
CONCLUSIONS: Most desired changes in prescribing did not occur. This was a small study with limited capacity to detect between-group differences, however, and so further studies are needed before the potential for harnessing the marketing resources of industry to conduct ‘academic detailing’ is ruled out.
SoumeraiSBAvornJ. Principles of educational outreach “academic detailing” to improve clinical decision making. JAMA.1990;263:549–556.
2.
LurieNRichECSimpsonDEPharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. J Gen Int Med.1990;5:240–243.
3.
PeayMPeayER. The role of commercial sources in the adoption of a new drug. Soc Sci Med.1988;26:1183–1189.
4.
GuyattGCookDJSackettDLEckmanMPaukerS. Grades of recommendations for antithrombotic agents. Chest.1998;114:441S–444S.
5.
MulrowCDCookDJDavidoffF. Systematic reviews: critical links in the great chain of evidence. Ann Int Med.1997;126:389–391.
6.
AvornJSoumeraiSB. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based “detailing.”N Engl J Med.1983;308:1457–1463.
7.
RayWASchaffnerWFederspielCF. Persistence of improvement in antibiotic prescribing in office practice. JAMA.1985;253:1774–1776.
8.
SchaffnerWRayWAFederspielCFMillerWO. Improving antibiotic prescribing in office practice. A controlled trial of three educational methods. JAMA.1983;250:1728–1732.
9.
SoumeraiSBAvornJ. Economic and policy analysis of university-based drug “detailing.”Med Care.1986;24:313–331.
10.
Ontario Anti-infective Review Panel.Anti-infective guidelines for community-acquired infections. 1. Toronto, Queen's Printer of Ontario; 1994.
11.
BluestoneCKleinJ. Otitis media in infants and children.Philadelphia, PA: W.B. Saunders; 1995.
12.
Drugs for treatment of acute otitis media in children.Med Letter.1994;36:19–21.
13.
SoumeraiSBAvornJ. Predictors of physician prescribing change in an educational experiment to improve medication use. Med Care.1987;25:210–21.
14.
SPSS Inc. SPSS for MS Windows Release 6.1.3. (6.1.3). 1995. Michigan, SPSS Inc.
15.
MeyerTJvanKootenDVMarshSReduction of polypharmacy by feedback to clinicians. J Gen Intern Med.1991;6:133–136.
16.
RayWABlazerWSchaffnerWFederspielCF. Reducing long-term diazepam precribing in office practice: a controlled trial of educational visits. JAMA.1986;256:2536–2539.
17.
McConnellTSCushingAHBankhurstADHealyJAMcIlvennaPASkipperBJ. Physician behaviour modification using claims data: tetracycline for upper respiratory infection. Western J Med.1982;137: 448–450.
18.
RaischDWBootmanJLLarsonLNImproving antiulcer agent prescribing in a health maintenance organization. Am J Hosp Pharm.1990;47: 1766–1773.
19.
PetersonGMBerginJKNelsonBJStantonLA. Inproving drug use in rheumatic disorders. J Clin Pharmacy Therapeutics.1996;21:215–220.
20.
HartlaubPPBarrettPH. Evaluation of an intervention to change benzodiazepine-prescribing behavior in a prepaid group practice setting. Am J Prev Med.1993;9:346–352.
21.
DeSantisGHarveyKJHowardDImproving the quality of antibiotic prescription patterns in general practice: the role of educational intervention. Med J Aust.1994;160:502–505.
22.
AvornJSoumeraiSBEverittDERoss-DegnanDBeersMHShermanDSalem-SchatzSRFieldsD. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med.1992;327:168–173.
23.
CulpepperLFroomJ. Routine antimicrobial treatment of acute otitis media: is it necessary?JAMA.1997;278:1643–1645.
24.
Hill-SmithI. Antibiotics as initial treatment for children with acute otitis media. Abandoning treatments that you have used for years is difficult. Br Med J.1997;315:880.
25.
Del MarCGlasziouPHayemM. Are antibiotics indicated as initial treatment for children with acute otitis media? A meta-analysis. Br Med J.1997;314: 1526–1529.
26.
RosenfeldRMVertressJECarrJCipolleRJUdenDLGiebinkGSCanafaxDM. Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from thirty-three randomized trials. J Pediatrics.1994;124:355–367.
27.
WiliamsREChalmersTCStantonLAChalmersFTBowlinSJ. Use of antibiotics in preventing recurrent acute otitis media and in treating otitis media with effusion. A meta-analytic attempt to resolve the brouhaha. JAMA.1993;270:1344–1351.
